Mechanism of Action
MOR-Selective Agonism
Endomorphin-1 binds MOR (Gi/Go-coupled GPCR) with Ki ~360 pM -- among the highest affinities for any endogenous opioid. Gi activation inhibits adenylyl cyclase (reducing cAMP), activates inward rectifier K+ channels (hyperpolarization), and blocks voltage-gated Ca2+ channels, reducing neurotransmitter release from presynaptic terminals. These effects produce profound spinal and supraspinal analgesia, respiratory depression (at high doses), and, at mesolimbic sites, reward and dopamine release.
Biased Agonism Potential
Research suggests endomorphins may preferentially activate Gi signaling over beta-arrestin2 recruitment compared to morphine, a "biased agonism" profile that predicts reduced tolerance and respiratory depression in preclinical models. The Trp residue at position 3 (unique among opioid peptides) contributes to this signaling profile. Biased MOR agonists designed around the endomorphin scaffold are a major focus of analgesic drug development.
Research Summary
Analgesia
Preclinical StrongIntrathecal endomorphin-1 produces potent dose-dependent analgesia in hot plate and tail flick tests, equivalent to morphine at equimolar doses. Supraspinal (ICV) administration similarly produces profound analgesia. Importantly, respiratory depression appears less severe than morphine at equi-analgesic doses in some rodent models, supporting the biased agonism hypothesis. Blood-brain barrier penetration of native EM-1 is limited, requiring modification for systemic delivery.
Stable Analog Development
Active ResearchMetabolic instability and poor BBB penetration of native endomorphins have driven synthesis of hundreds of analogs with N-methylation, D-amino acid substitution, glycosylation, and lipidation. Several analogs show systemic activity with equal or greater potency than morphine with potentially reduced tolerance, constipation, and respiratory depression. Phase 1 trials of endomorphin-based analgesics are in early planning.
Cardiovascular and Immune Effects
Active ResearchMOR activation by endomorphins in the heart reduces ischemia-reperfusion injury. Peripheral MOR on immune cells modulates cytokine production. Endomorphin-1 has anti-inflammatory effects in multiple inflammatory models via MOR-mediated immunosuppression and direct reduction of pro-inflammatory cytokines from macrophages.
Calculate your Endomorphin-1 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Spinal analgesia research | 1-10 nmol intrathecal (rodent) | Per session | Intrathecal |
| Supraspinal analgesia research | 10-100 nmol ICV (rodent) | Per session | ICV |
| Peripheral anti-inflammatory | 10-50 nmol SC or IP in inflammatory models | Per session or daily | Subcutaneous or intraperitoneal |
Native EM-1 rapidly degraded by prolyl endopeptidase and aminopeptidases. Metabolically stable analogs (2'-methyltyrosine, D-Pro substitutions) recommended for longer-lasting effects in vivo.
Interactions
Safety Profile
Research dose profiles: analgesia, mild sedation, and reduced locomotion at effective analgesic doses. Respiratory depression less pronounced than morphine at equi-analgesic intrathecal doses in preclinical studies, but still present at supraspinal levels. Constipation and reward/reinforcement effects via MOR in gut and mesolimbic circuits. Rapid enzymatic degradation limits systemic toxicity of native peptide. Analog programs focus specifically on separating analgesia from respiratory depression and addiction liability through biased agonism optimization.